DUALITYBIO-B (09606) has announced that on April 13, 2026, its board of directors approved a proposed issuance of RMB-denominated shares for listing on the STAR Market, a special authorization, and related matters. The proposal is subject to approval by shareholders at an extraordinary general meeting and the receipt of necessary regulatory approvals. The total funds raised from the RMB share issuance are expected not to exceed 6.75 billion yuan. After deducting issuance expenses, the net proceeds will be used entirely for projects related to the company's main business. The company proposes to issue no more than 15.77919 million RMB shares. The company and the lead underwriter may agree to exercise an over-allotment option, which would allow the issuance of additional RMB shares not exceeding 15% of the initial number of shares to be issued.